Extended Data Fig. 3: The combination of sorafenib and the EGFR inhibitor gefitinib shows no synergy in liver cancer cells in vitro. | Nature

Extended Data Fig. 3: The combination of sorafenib and the EGFR inhibitor gefitinib shows no synergy in liver cancer cells in vitro.

From: EGFR activation limits the response of liver cancer to lenvatinib

Extended Data Fig. 3

af, Liver cancer cell lines were treated with sorafenib, the EGFR inhibitor gefitinib or their combination at the indicated concentrations. The cells were fixed and stained after 10–14 days. Representative data from three independent experiments. gl, The quantification of the three independent assays shown in af. Data are mean ± s.e.m., n = 3 independent experiments

Source data.

Back to article page